quest for growth...3 2018 h1 results and performance quest for growth key facts: • return on...
TRANSCRIPT
1
Quest for Growth
Press & Analyst Meeting
27 July 2018
2
Agenda
2018 H1 results and performance Quest for Growth
Comments on quoted portfolio
Comments on unquoted portfolio
Stock dividend
Questions and Answers
3
2018 H1 results and performance Quest for Growth
Key facts:
• Return on equity per share: -0.33% since 31 December 2017
• Net asset value per share at 30 June 2018: € 8.69 (31 December 2017: € 10.71)
• Net result for the period: - € 560,133 (- € 0.04 per ordinary share) against a profit of € 22,104,883 (+ € 1.27 per
ordinary share) for H1 2017
• Share price at 30 June 2017: € 7.50 (31 December 2017: € 8.811)
• Discount of the share price versus net asset value: 13.72 % at 30 June 2018 (17.75 % at 31 December 2017)
• New indirect investment in DMC (CSCF)
• Stock dividend: 53% conversion
• Capital increase: €11,171,831 (net of cost)
4
2018 H1 results and performance Quest for Growth Added value per sector per share
5
2018 H1 results and performance Quest for Growth Added value per asset class per share
6
Quest for Growth NAV Results from 1/01/2008 until 30/06/2018
7
Quest for Growth share price 10 year total shareholders return
8
Quest for Growth share price Discount to Net Asset Value: 13.72 %
9
Quest for Growth share price Portfolio composition and market capitalisation at 30/06/2018
10
Distribution of the portfolio by sector
at 30/06/2018
11
Agenda
2018 H1 results and performance Quest for Growth
Comments on quoted portfolio
Comments on unquoted portfolio
Stock dividend
Questions and Answers
12 source: Bloomberg
Stock markets in Europe & USA
Portfolio quoted Equity market environment
Equity markets in 2018
13
Portfolio quoted Equity market environment
Equity markets in 2018
source: Bloomberg
Sector performance in Europe
14
Portfolio quoted Equity market environment
Valuation
source: Factset, Capricorn Venture Partners
STOXX Europe 600 12 month forward P/E
15
Portfolio quoted Transactions 2018
IN OUT INCREASE REDUCTION
Axway Technotrans Tomra
Gerresheimer
Nexus
Gerresheimer CEWE Tomra
Cenit Umicore
Kingspan
Accell Group Jensen-Group
Nexus Stratec Biomedical
Fresenius Avantium
Avantium Corbion
DAX put Jun-18 Nexus
TKH
Tomra
Bertrandt
Akka Technologies Bertrandt Kingspan
JANUARY
FEBRUARY
MARCH
APRIL
MAY
JUNE
16
Portfolio quoted Transactions 2018 H1: Positions fully sold
17
Portfolio quoted Transactions 2018 H1: Sale Bertrandt
source : Bloomberg, Capricorn Venture Partners
18
Portfolio quoted Transactions 2018 H1: Introduction Akka Technologies
Akka Technologies offers engineering and
technology consulting services, mainly in the
field of automotive and aeronautic projects but
also within the rail sector and in life sciences.
The company was founded in 1984.
19
Portfolio quoted Top 10 holdings
country sector/activityportfolio
entry% NAV
TKH Group Netherlands telecom, building and industrial solutions 2014 4.6%
Pharmagest France software for pharmacies 2010 4.5%
CEWE Germany photo and online printing services 2017 4.4%
Norma Group Germany connection technology and water mgmt. 2016 4.3%
Fresenius SE Germany healthcare products and services 2012 3.9%
Aures France point-of-sale terminals 2017 3.7%
Stratec Biomedical Germany equipment for diagnostics and life sciences 2017 3.4%
Technotrans Germany liquid technology 2015 3.3%
Jensen-Group Germany heavy-duty laundry equipment 2016 3.1%
Cenit Germany PLM software & services 2017 3.1%
20
Portfolio quoted Valuation of portfolio companies: 12m fwd. P/E = 20.1
12 month forward P/E of portfolio companies
source : Factset, Capricorn Venture Partners
21
Portfolio quoted Financial strength
Net debt/EBITDA 2018e of portfolio companies
source : Factset, Capricorn Venture Partners
22
Portfolio quoted 2018 H1 result
Source: Bloomberg, Capricorn Venture Partners
QfG quoted (e) is estimate excluding costs and cash
Portfolio company returns in local currency
23
Portfolio quoted Performance attribution 2018 H1
Source: Factset, Capricorn Venture Partners
Stock Contrib.% Stock Contrib.%
1 Pharmagest Interactive SA 1.7 1 EVS Broadcast Equipment SA -1.2
2 AURES Technologies 1.3 2 Accell Group N.V. -0.8
3 TOMRA Systems ASA 0.8 3 CENIT AG -0.8
4 Kingspan Group Plc 0.7 4 technotrans AG -0.7
5 Umicore 0.6 5 JENSEN-GROUP NV -0.6
Estimated gross (excl. fees & cash) performance QfG Quoted Portfolio: 1%
TOP POSITIVE CONTRIBUTIONS TOP NEGATIVE CONTRIBUTIONS
24
Agenda
2018 H1 results and performance Quest for Growth
Comments on quoted portfolio
Comments on unquoted portfolio
Stock dividend
Questions and Answers
25
Portfolio unquoted
26
Portfolio unquoted
• Fully depreciated compared to fair value of EUR 68,496 per December 31, 2017
• No expectation for a significant revenue due to further dilution of position QfG
27
Portfolio unquoted
direct investments – co-investments
28
Portfolio unquoted
Venture Capital Funds
Capricorn Cleantech Fund (CCF)
Press release Avantium: AMSTERDAM, 12 January 2018 – Avantium N.V. today announces that Synvina, its joint venture with BASF, plans to extend the pilot phase in order to optimize future commercial-scale production.
End of lock-up period: 16 March 2018
29
Portfolio unquoted
Venture capital funds
30
Portfolio unquoted
Venture Capital Funds
Capricorn Health-tech Fund (CHF)
New CEO Jason Hannon has been performing well and impressed investors. His priorities
are:
• Completing the ongoing trial and the PMA submission (the interim reading of the
trial in December 2017 was positive, the DMC had no safety concerns and
recommended sticking to 168 patients in the study). Trial read out is expected
by the end of 2018
• Launching commercial efforts in Germany is a priority
Company completed a € 30M raise in February with significant participation from major existing shareholders and the Irish Sovereign fund.
Capital increase
31
Portfolio unquoted
Venture Capital Funds
Capricorn Health-tech Fund (CHF)
• The enrolment in the E-FIT trial (post-stroke rehabilitation) has been completed in January
and results are expected end of the summer.
• The company launched the commercialization of the Navigated Brain Therapy (NBT®)
System for the treatment of Major Depressive Disorder (MDD) in the USA and has announced
already a first sale in May.
• CHF purchased via a direct issuance 4,000,000 of Nexstim's shares.
Nexstim: € 1,000,000 follow on investment
32
Portfolio unquoted
Venture Capital Funds
Capricorn ICT Arkiv (CICT)
On January 19th, LindaCare closed a Series B round of €7 million led by Philips Health
Technology Ventures (US / Netherlands) and joined by PMV (Flanders).
The investment will be used to help LindaCare accelerate its US market expansion and product
commercialization. It will also support the building of new services around the existing software
platform and explore options for expanding its products to a broader range of cardiac diseases.
LindaCare’s first product, OnePulseTM, has been successfully installed and is in use in a number
of major hospitals in Europe, as well as being launched in its first pilot projects in the US.
Capital increase
33
Portfolio unquoted
Venture Capital Funds
Capricorn Sustainable Chemistry Fund (CSCF)
34
Portfolio unquoted
Venture Capital Funds
Life Sciences Partners IV
ARGX.BR 17/07/2017 - 2/08/2018 (BRU)
Line; ARGX.BR
16/07/2018; 75,2000
Price
EUR
Auto
18
20
22
24
26
28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
17 24 31 07 14 21 28 04 11 18 25 02 09 16 23 30 06 13 20 27 04 11 18 27 02 08 15 22 29 05 12 19 26 05 12 19 26 03 09 16 23 30 07 14 21 28 04 11 18 25 02 09 16 23 30juli 2017 augustus 2017 september 2017 oktober 2017 november 2017 december 2017 januari 2018 februari 2018 maart 2018 april 2018 mei 2018 juni 2018 juli 2018
• ARGX-110 (anti-CD70): reported that all 6 Acute Myeloid Leukemia (AML) patients in the Phase 1/11 study responded
to ARGX-110 + Vidazia.
• ARGX-113 (anti-FcRn; degrade autoimmune Abs): reported positive Phase 11 efgartigimod (ARGX-113) data in
myasthenia gravis (MG) showing statistically significant MG-ADL score improvement in 75% of patients (vs. only 25%
of placebo).
• ArgenX closed US public offering for gross proceeds of USD 266 mln. Over the course of Q1, the share price moved
from €18.50 to €52.52 (285% increase). Over the course of Q2, the share price moved from € 52.52 to €65.20
(24% increase). Current share price is about €75
• LSP IV invested 7,57 million. Valuation in the books of LSP IV at the end of March was 97,20 million.
• Quest for Growth has a 2,3% stake in LSP IV.
35
Agenda
2018 H1 results and performance Quest for Growth
Comments on quoted portfolio
Comments on unquoted portfolio
Stock dividend
Questions and Answers
36
Financial calendar 2018 Optional dividend in shares
Terms of the offer
# shares: 15.155.969
# rights exercised: 8.091.285
Percentage exercised: : 53,39%
# newly issued shares: 1.618.257
# shares post stock dividend: 16.774.226
Gross amount of capital increase: 11.327.844
Cost of capital increase: -156013,05
Net amount of capital increase: 11.171.831
Capital pre stock dividend: 135.130.875
Capital post stock dividend: 146.458.719
Capital post stock dividend (IFRS) 145.339.326
Dilution existing shareholders: 2,04
37
Financial calendar 2018
38
Agenda
2018 H1 results and performance Quest for Growth
Comments on quoted portfolio
Comments on unquoted portfolio
Stock dividend
Questions and Answers
39
Thank you for your attention!